Barely Significant
← all phrases

“nominally significant”

7,733 sentences · 7,733 papers · 10,034 search hits before verification · confirmed specimen

Sighted at

p=0.08

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

In SUSTAIN 6, nominally significant heterogeneity of semaglutide efficacy by baseline BMI was observed for CV death/myocardial infarction/stroke (major adverse CV events, primary outcome of both; P interaction = .02); otherwise, there was no statistical heterogeneity for either GLP‐1 RA versus placebo across BMI categories for key CV and kidney outcomes.
First, we have previously shown that it is possible to identify real copy number changes at VNTR loci using short oligonucleotide arrays [35] ; second, copy number changes at this locus were identified by multiple platforms in the current study; third, the association is nominally significant in both the Utah and Porto cohorts; fourth the locus is within the AZFb/c region.
These variants included; Ecotropic Viral Integration Site 5 ( EVI5 ) rs11808092 (OR: 2.04, 95%CI: 1.4–2.9), TNF Receptor Superfamily Member 1 A ( TNFRSF1A ) rs1800693 (OR: 2.01, 95%CI: 1.45–2.75), Lymphocyte Function-Associated Antigen 3 ( CD58 ) rs1414273 (OR: 2.2, 95%CI: 1.5–3.2), and a nominally significant and not clearly robust Methylenetetrahydrofolate Reductase ( MTHFR ) variant rs1801131 (OR: 1.4, 95%CI: 1.02–1.9).
Conditional analysis of the top OPRM1 variants (rs1799971 and rs79704991; r 2 = 0.02) demonstrated that these variants are not independent as indicated by each variant falling below GWS when conditioned on the other; however, the variant effects remained nominally significant and there were no significant differences in the conditioned vs. unconditioned effect sizes.
The treatment difference observed at Month 1 ( P < 0.001) was nominally significant because of the multiplicity step‐down procedure employed. 3.4 MSHQ bother domain Baseline MSHQ bother scores were similar between treatment groups, with the mean (SD) scores of 16.7 (3.36) and 17.1 (3.18) in the DUT‐TAM FDC therapy group and in the placebo group, respectively.